HC Wainwright Has Negative Forecast for Evotec Q3 Earnings

Key Points

• HC Wainwright has revised Evotec's Q3 2025 earnings estimate to ($0.05) per share, down from a prior estimate of ($0.04), while maintaining a "Buy" rating with a target price of $7.00.
• Current consensus estimates for Evotec's full-year earnings are expected to be ($0.41) per share, with forecasts showing improvements in subsequent years.
• Recent trading data shows Evotec shares opened at $3.76, with notable institutional investments increasing ownership in the company.

Evotec AG (NASDAQ:EVO - Free Report) - Research analysts at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Evotec in a report released on Thursday, August 14th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.05) for the quarter, down from their prior forecast of ($0.04). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q4 2025 earnings at $0.22 EPS, FY2025 earnings at ($0.09) EPS, Q1 2026 earnings at ($0.02) EPS, Q2 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.30 EPS, FY2028 earnings at $0.39 EPS and FY2029 earnings at $0.53 EPS.

EVO has been the topic of a number of other research reports. Royal Bank Of Canada restated an "outperform" rating on shares of Evotec in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a research report on Thursday, April 24th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $5.40.

Evotec Price Performance

Shares of NASDAQ:EVO traded up $0.10 during midday trading on Monday, hitting $3.64. The company had a trading volume of 50,424 shares, compared to its average volume of 52,923. The company has a current ratio of 1.58, a quick ratio of 1.49 and a debt-to-equity ratio of 0.42. Evotec has a 12-month low of $2.84 and a 12-month high of $5.64. The company has a fifty day moving average of $4.00 and a two-hundred day moving average of $3.95.

Hedge Funds Weigh In On Evotec

Several large investors have recently modified their holdings of EVO. DCF Advisers LLC increased its position in shares of Evotec by 227.0% during the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock valued at $2,510,000 after purchasing an additional 521,708 shares during the last quarter. WCM Investment Management LLC bought a new stake in shares of Evotec during the 2nd quarter worth approximately $1,239,000. Pitcairn Co. bought a new stake in shares of Evotec during the 2nd quarter worth approximately $1,097,000. Envestnet Asset Management Inc. bought a new stake in shares of Evotec during the 2nd quarter worth approximately $385,000. Finally, ABC Arbitrage SA bought a new stake in shares of Evotec during the 1st quarter worth approximately $260,000. Institutional investors own 5.81% of the company's stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.